BIOLASE Receives FDA Clearance for the EPIC 10S Soft Tissue

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
BIOLASE Receives FDA Clearance for the EPIC 10S Soft Tissue Diode Laser for a Broad Spectrum of Medical Procedures

IRVINE, CA--(Marketwired - Apr 11, 2013) - BIOLASE, Inc. ( NASDAQ : BIOL ), the world's leading manufacturer and distributor of dental lasers, announced today that the U.S. Food and Drug Administration (FDA) has cleared the EPIC 10S™ soft tissue diode laser for use as a surgical instrument for over 80 different indications in 19 medical markets including: ear, nose and throat, oral surgery, arthroscopy, gastroenterology, orthopedics, general surgery, dermatology, plastic surgery, podiatry, GI/GU, gynecology, neurosurgery, ophthalmology, pulmonary surgery, cardiac surgery, thoracic surgery, urology, dermatology, aesthetics, and vascular surgery (see Exhibit A for a detailed listing of medical markets and indications). The EPIC 10S is the surgical model of the recently released, next-generation dental EPIC 10™.

"We are extremely pleased to receive clearance for such a broad number of indications and procedures for our EPIC platform. The clearance for the EPIC 10S is based on the clearance we received in February 2013 for our older Diolase soft tissue diode laser and, needless to say, we are extremely happy to have received it so quickly," said Federico Pignatelli, Chairman and Chief Executive Officer. "This clearance gives us the ability to leverage our EPIC 10™ modular soft tissue diode laser platform and consumable business across a wide range of multi-billion dollar medical markets with appropriate strategic partners or in a direct mode. With the vast number of procedures now available for the EPIC, the opportunities for this new modular platform are tremendous."

BIOLASE's diode lasers are currently used in dentistry for a wide variety of surgical soft tissue procedures as an alternative to invasive and traumatic conventional devices, such as the high-speed drill, scalpel, or electrosurge. The 940nm laser wavelength of the EPIC 10 platform is better absorbed by hemoglobin (Hb) and oxyhemoglobin (HbO 2 ) than other diode laser wavelengths, so it cuts efficiently at low power and with considerably less heat and discomfort, making it an excellent alternative to conventional surgical devices. BIOLASE's EPIC 10 940nm wavelength diode laser uses disposable tips which help reduce the risk of infection and cross contamination and is also FDA cleared for tooth whitening and temporary pain relief.

"It is truly remarkable to see how our core technologies can impact so many other medical fields. Our 940nm diode lasers are excellent alternatives to conventional surgical devices and we have already begun performing clinical studies for a variety of these new applications and some of our early results have been extraordinary," said Fred Furry, Chief Operating Officer and Chief Financial Officer. "Our plan remains to focus on growing our core laser business in the dental market but we will also continue to expand the capabilities, applications, and indications for these core technologies in other medical markets, as well."

Exhibit A - Detailed Listing of Medical Markets and Indications for Use

Ear, Nose and Throat and Oral Surgery: Hemostasis, incision, excision, ablation, and vaporization of tissues from the ear, nose, throat and adjacent areas, including soft tissue in the oral cavity, such as:

  • Removal of benign lesions from ear, nose and throat
  • Excision and vaporization of vocal cord nodules and polyps
  • Incision and excision of carcinoma in-situ
  • Ablation and vaporization of hyperkeratosis
  • Laryngeal papillectomy
  • Excision and vaporization of herpes simplex I and II
  • Neck dissection

Arthroscopy: Hemostasis, incision, excision, vaporization, and ablation of joint tissues during arthroscopic surgery, such as:

  • Menisectomy
  • Syovectomy
  • Chondromalacia

Gastroenterology: Hemostasis, incision, excision, and vaporization of tissue in the upper and lower gastrointestinal tracts via endoscopy, such as:

  • Hemostasis of upper and lower GI bleeding
  • Excision and vaporization of colorectal carcinoma
  • Excision of polyps
  • Hemostasis of colonoscopy
  • Hemostasis of esophageal varices

Orthopedics:

  • Dissect and coagulate

General Surgery, Dermatology & Plastic Surgery, and Podiatry: Excision, ablation, vaporization, and photocoagulation of skin lesions, hemostasis, incision, excision, vaporization, ablation, and debulking of soft tissue, abdominal, rectal, skin, fat or muscle tissue, and dermabrasion, such as:

  • Matrixectomy
  • Excision of neuromas
  • Excision of periungual and subungual warts
  • Excision of plantar warts
  • Excision of Keloids
  • Excision of cutaneous lesions
  • Hemorrhoidectomy
  • Appendectomy
  • Debridement of decubitus ulcer
  • Hepatobiliary
  • Mastectomy
  • Dermabrasion
  • Vaporization & hemostasis of capillary hemangioma
  • Excision, vaporization & hemostasis of abdominal tumors
  • Excision, vaporization & hemostasis of rectal pathology
  • Pilonidal cystectomy
  • Herniorraphy
  • Adhesiolysis
  • Parathyroidectomy
  • Laparoscopic cholecystecomy
  • Thyroidectomy
  • Resection of organs

GI/GU: Excision, vaporization, and hemostasis of abdominal and rectal tissues, such as:

  • Hemorrhoidectomy
  • Excision, vaporization, and hemostasis of rectal pathology
  • Excision, vaporization, and hemostasis of abdominal tumors

Gynecology: Ablation, excision, hemostasis, and vaporization of tissue, such as:

  • Excision or vaporization of condylomata acuminata
  • Vaporization of CIN (cervical intraepithelial neoplasia)
  • Cervical conization
  • Menorrhagia
  • Ovarian cystectomy

Neurosurgery: Vaporization, coagulation, excision, incision, ablation and hemostasis of tissue, such as:

  • Hemostasis in conjunction with meningiomas
  • Percutaneous Disc Decompression (PLDD)

Ophthalmology:

  • Dacryocystorhinostomy transcanalicular
  • Open DCR
  • Tumor Excision
  • Blepharoplasty

Pulmonary Surgery: Hemostasis, vaporization, and excision of tissue, such as:

  • Tracheobronchial malignancy or stricture
  • Benign and malignant pulmonary obstruction

Cardiac Surgery:

  • Coagulation and hemostasis of cardiac tissue

Thoracic Surgery:

  • Thoracotomy
  • Pulmonary resection
  • Hemostasis
  • Pericardiectomy
  • Adhesiolysis
  • Coagulation of blebs and bullae

Urology: Hemostasis, vaporization, incision, coagulation, ablation, and excision of tissues, such as:

  • Vaporization of urethral tumors
  • Release of urethral stricture
  • Removal of bladder neck obstruction
  • Excision and vaporization of condyloma
  • Lesions of external genitalia
  • Circumcision
  • Vaporization of the prostate to treat benign prostate hyperplasia (BPH)

Dermatology/Aesthetics:

  • Photocoagulation of vascular & dermatological lesions of the face and extremities
  • Photocoagulation of telangiectasia, venulectasia of the legs and face
  • Treatment of reticular veins and branch varicosities
  • Pyrogenic granuloma, lymphangioma and lymphangiomatosis disease, angiofibromas
  • Superficial benign vascular lesions including Telangiectasias, hemangioma, Port wine stains, angiokeratoma, and benign epidermal pigment lesions as lentigines, epidermal nevi, spider nevi
  • Dermatological surgery: Condyloma acuminate, warts, small non-malignant skin tumors, small semi-malignant tumors as basaliomas, Bowe and Kaposi sarcoma, warty leucoplasty and ulcers debridement
  • Seborrheic keratosis
  • Mixoid cyst
  • Papillary varix
  • Acne treatment

Vascular Surgery:

  • Photocoagulation of vascular & dermatological lesions of the face and extremities
  • Photocoagulation of telangiectasia, veinulectasia of the legs and face
  • Treatment of reticular veins and branch varicosities

About BIOLASE, Inc. BIOLASE, Inc. is a biomedical company that develops, manufactures and markets dental lasers and also distributes and markets dental imaging equipment ; products that are focused on technologies that advance the practice of dentistry and medicine . The Company's laser products incorporate over 340 patented and patent-pending technologies designed to provide biologically clinically superior performance with less pain and faster recovery times. Its imaging products provide cutting-edge technology at competitive prices to deliver the best results for dentists and patients. BIOLASE's principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications, and a full line of dental imaging equipment. BIOLASE has sold more than 22,000 lasers. Other products under development address ophthalmology and other medical and consumer markets.

For updates and information on WaterLase and laser dentistry, find BIOLASE online at www.biolase.com , Facebook at www.facebook.com/biolaseinc , Twitter at twitter.com/biolaseinc , and YouTube at www.youtube.com/biolasevideos .

For further information, please contact: Michael Porter Porter, LeVay & Rose, Inc. 212-564-4700

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Daqo New Energy Faces Key Investor Meeting in December

Updated Category News Views 88

Spotlight on December's Agenda for Daqo Shareholders Who'd have thought we'd be looking at another year end with the same burning energy interests? Daqo New Energy Corp. (NYSE: DQ) is setting up for its annual general meeting (AGM) dated December 10, 2026. Mark your calendars, because these gatherings can be more than just straightforward affairs; sometimes they reveal...

Continue Reading
Bacterial Breakthrough in Cancer Therapy: Game Changer?

Updated Category News Views 7

Blurring Lines Between Bugs and Biotech Well, wouldn't you know it, the eggheads over at Jeonbuk National University in South Korea are at it again, pushing the boundaries of what these little bacterial buggers can do. This time, they’ve had a crack at cancer therapy, using engineered Salmonella to pack a double punch against breast cancer in mice. Now, if that ain't...

Continue Reading
IQSTEL's Nine-Month Revenue Hits $313M, Growth Impresses

Updated Category News Views 41

Pushing Through With Persistence Well, well, well, here we are, talking about IQSTEL Inc. (NASDAQ: IQST) slinging some serious numbers—not the kind you can ignore at your breakfast table. The company pulled in a whopping $313 million in revenue over the first nine months of 2026. That’s a bump up by 34.5% from last year’s $232.7 million. What’s behind the magic...

Continue Reading
AdMaven's Mave AI: Revolutionizing Campaign Management

Updated Category News Views 19

Taking the Tedious Out of Advertising You've got to love it when technology actually makes life easier, rather than more complicated. AdMaven's latest fancy toy, the AI assistant Mave, is promising just that. It's designed to take the heavy lifting off advertisers' shoulders, especially the day-to-day grind of tweaking ad settings and monitoring performance. If you've...

Continue Reading
Dawson Struggles With Q3 Losses Despite Growth Prospects

Updated Category News Views 42

Profit and loss dance around like a jittery stock, and Dawson Geophysical is feeling the heat this third quarter. Numbers are in, and we’re seeing a net loss of $5.2 million, translating to $0.17 per share—ouch. Not to mention a negative Adjusted EBITDA of $2 million. Compared to last year's hopes, that's a serious belly flop. Revenue Down, Hopes Up In a fetching...

Continue Reading
DoGo Power Revamps Energy for Remote Indonesian Isle

Updated Category News Views 114

Bringing Light to Pagerungan Kecil Island These days, if you wander into the fishing communities of Pagerungan Kecil Island, the buzz isn't just from the daily catch. Residents are talking about power, and not the kind you get from a generator spluttering along—I'm talking about a brand-new energy storage system that’s turning the lights on in ways these folks have...

Continue Reading
Roche Delivers Endotrophin Assay to Nordic Bioscience Lab

Updated Category News Views 52

Roche Opens New Frontier in Diagnostic Biomarkers Get ready to chew on this: Roche Diagnostics is bringing something new to Nordic Bioscience's CLIA lab. They're offering up their Endotrophin research prototype assay on the cobas® e801 Analyzer. Now, what does this mean for the scientific world? Well, it might just shake things up for those battling cardiovascular and...

Continue Reading
DarioHealth's New Research Tackles Healthcare Cost Estimation

Updated Category News Views 91

Unpacking Dario's Bold Surgical Strike at ISPOR Europe Alright, folks, DarioHealth is shaking up the stage with their new methodology that could very well carve a new path in how we size up digital healthcare savings. Presented at ISPOR Europe 2026, Dario's tactic bypasses the sluggish wait on medical claims data, instead offering an evidence-driven peek at potential...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 147

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
ICCSD in Beijing: AI and Culture's Future Explored

Updated Category News Views 136

AI's Intersection with Culture in the Spotlight Imagine a room full of people hammering out the future of AI and culture—it starts to feel like a melting pot for the mind. That was the scene in Beijing when the ICCSD Advisory Committee congregated on October 26, 2026. With experts pooling from four different countries, there was no shortage of fireworks. They hashed out...

Continue Reading

Top 5 Most Recently Viewed Articles

Piper Sandler Welcomes John Kerins to Healthcare Team

Updated Category News Views 218

Piper Sandler Expands Healthcare Investment Banking Expertise Piper Sandler Companies (NYSE: PIPR), a prominent name in investment banking, is excited to announce a significant addition to their healthcare investment banking team with the hiring of John Kerins as a managing director. This strategic move reflects the firm’s commitment to strengthening its presence in the...

Continue Reading
Exploring North America's Last Mile Delivery Growth and Trends

Updated Category News Views 346

Exploring North America's Last Mile Delivery Growth and Trends The last mile delivery market in North America is poised for significant growth over the next few years. Experts estimate that this market could expand by USD 14.9 billion between 2025 and 2029. This impressive growth is being driven primarily by the increasing demand for business-to-consumer (B2C) e-commerce....

Continue Reading
Mastercard Marks 20 Years on NYSE with Digital Shift

Updated Category News Views 39

A Landmark Moment at the NYSE for Mastercard Ah, another day in the whirlwind of the stock universe, where birthdays are celebrated with the finesse of boardroom discussions. Mastercard (NYSE: MA) is taking a well-deserved spotlight as it cheers two decades since it hit the seal of the New York Stock Exchange. Back on May 26th, it wasn't just business as usual. Nope, they...

Continue Reading
Insights into the Expanding Network of China-Europe Freight Trains

Updated Category News Views 236

The Rise of China-Europe Freight Trains Recently, a significant milestone was reached when the 110,000th China-Europe freight train departed from Jiaozhou Station, fully loaded with various goods such as electronic displays and household appliances. This service has now transported goods worth over USD 450 billion, showcasing its crucial role in global trade. The Journey...

Continue Reading
Netflix Investors Encouraged to Report Losses Amid Investigation

Updated Category News Views 217

Investigation Focus on Netflix, Inc. (NASDAQ: NFLX) Recently, significant scrutiny has emerged surrounding Netflix, Inc. (NASDAQ: NFLX), as Edelson Lechtzin LLP, a prominent national law firm known for handling class action lawsuits, initiates an investigation into potential violations of federal securities laws. This inquiry seeks to determine whether Netflix and certain...

Continue Reading